Entresto vs Vascepa
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Entresto | US Vascepa | |
|---|---|---|
| Generic name | sacubitril/valsartan | icosapent ethyl |
| Drug class | ARNI (Neprilysin Inhibitor + ARB) | Omega-3 Fatty Acid (EPA) |
| Treats | Chronic heart failure | High triglycerides, cardiovascular risk reduction |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Novartis | Amarin |
| Year approved | 2015 | 2012 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $150M | $90M |
| Common side effects | Low blood pressure, High potassium, Kidney problems, Dizziness | Atrial fibrillation, Bleeding risk, Joint pain, Swelling |
Frequently asked questions
Is Entresto or Vascepa better?
Neither is universally "better." Entresto (sacubitril/valsartan) and Vascepa (icosapent ethyl) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Entresto and Vascepa?
Entresto is a ARNI (Neprilysin Inhibitor + ARB) made by Novartis, while Vascepa is a Omega-3 Fatty Acid (EPA) made by Amarin. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Entresto has the larger estimated TV advertising budget of the two.